Liver Transplant RejectionNCT04514666
VOCs in Kidney and Liver Transplants
A study testing Breath analysis in people with Liver Transplant Rejection and Kidney Transplant; Complications, run by Societa Italiana di Chirurgia ColoRettale at 1 site in Italy.
Trial summary
Kidney and liver trasplants represent very challenging lifesaving and effective surgical procedures for patients with end-stage kidney and/or liver disease. Chronic rejection may occur in 3 to 17% livers transplants and in 20 to 40% kidney transplants. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Liver Transplant Rejection, Kidney Transplant; Complications
- What is being tested?
- Breath analysis
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteItaly
- Study dates
- 2 Oct 2021to 2 Mar 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Both sex
- Patients eligible for liver or kidney transplant
- Written informed consent
Who cannot join
- Acute liver failure
- Acute liver and kidney rejection
- HCC
- Re-transplant
- Pregnancy
- IBD
- Any psychiatric disease
Trial locations and contacts
1 site in 1 country.
Italy1 site
Dept of Emergency and Organ transplantation
Bari, 70124
Arcangelo F Picciariello, MD, 00393492185104, arcangelopicciariello@gmail.com
Arcangelo Picciariello, MD
About this study
Official title: Exhaled Volatile Organic Compounds as Potential Predictive Biomarkers of Chronic Kidney and Liver Rejection After Transplants
Kidney and liver trasplants represent very challenging lifesaving and effective surgical procedures for patients with end-stage kidney and/or liver disease.
Chronic rejection may occur in 3 to 17% livers transplants and in 20 to 40% kidney transplants.
Read more
While acute rejection is clearly detected due to the clinical features and laboratory tools, the early identification of chronic rejection is still challenging since the clinical features are often silents and laboratory tests become suggestive when the damage due to the rejection is almost irreversible.
Considering the recent application of the breathomic to liver and kidney disease and the difficulty in the early detection of chronic rejection after liver and kidney transplants, the analysis of the exhaled VOCs pattern could help early detection of chronic rejection allowing a prompt medical treatment.
Read the detailed description
Kidney and liver trasplants represent very challenging lifesaving and effective surgical procedures for patients with end-stage kidney and/or liver disease.
Nowadays the short and long term success rate of kidney and liver trasplants is pretty hight. Nevertheless, transplant rejection remains one of the biggest limitations with a strong impact on patients survival.
Usually acute rejection occurs within 3 months after the transplant and is the most common cause of transplant failure and the most common indication for re-transplantation .
Chronic rejection may occur in 3 to 17% livers transplants and in 20 to 40% kidney transplants.
While acute rejection is clearly detected due to the clinical features and laboratory tools, the early identification of chronic rejection is still challenging since the clinical features are often silents and laboratory tests become suggestive when the damage due to the rejection is almost irreversible.
Chronic renal transplant rejection is the result of a gradual decrease in the kidney function that starts to become evident three months after surgery.
Kidney chronic rejection is, by definition, immune-mediated and generally divides into chronic active antibody-mediated rejection and chronic active T cell-mediated rejection.
Transplant vasculopathy is the single most important feature of chronic renal transplant rejection and it is the direct consequence of an immune reaction that activates a cytokines cascade with a tissue fibrosis and chronic rejection.
Hypertension and proteinuria are the most important features of declining renal function.
Laboratory tests such as serum creatinine and estimated glomerular filtration rate (eGFR)ccan help to early identify kidney allograft dysfunction. The eGFR is suggested to be a more accurate indicator and predictor of graft function and long term graft loss.
However, a biopsy is mandatory for diagnosing chronic renal transplant rejection. C4d complement fragment deposition in the peritubular capillaries represents the marker for antibody-mediated tissue injury.
Although the incidence of acute and chronic rejection has declined with improvement of immunosuppression regimens, chronic rejection may lead to re-transplant or death.
Chronic liver allograft rejection usually occurs more than 2 months after transplantation and most frequently develops after an unresolved or multiple episodes of acute rejection or indolently over a period of months to years, with few or no clinically apparent acute cellular rejection episodes.
Chronic rejection characterized primarily by fibrointimal hyperplasia of arteries, or obliterative arteriopathy, interstitial fibrosis and atrophy of parenchymal elements.
Often the only reliable early indicator of chronic rejection is persistent and preferential elevation of γ-glutamyl transpeptidase and alkaline phosphatase, which is related to bile duct damage. In most of cases the only clinical sign is jaundice and it appears when allograft dysfunction becomes. Biliary sludging or appearance of biliary strictures, hepatic infarcts, and finally loss of hepatic synthetic function, which can manifest as coagulopathy, malnutrition, and hepatosplenomegaly are late findings presaging allograft failure. Biopsy is mandatory to assess the liver damage.
Breath analysis (Breathomics) is applied widely nowadays in clinical setting in order to identify and evaluate exhaled molecular volatile compounds as expression of a metabolic derangement of the organism including chronic diseases and cancer disease.
A novel approach, a breath test based on the metabolomic evaluation of the volatile organic compounds (VOCs) in the exhaled breath, has recently been developed by our group to identify patients with Colorectal cancer, showing good reliability and compliance.
VOCs analysis has also been demonstrated to find an application in the diagnosis of chronic liver and kidney disease with high sensitivity and specificity.
Considering the recent application of the breathomic to liver and kidney disease and the difficulty in the early detection of chronic rejection after liver and kidney transplants, the analysis of the exhaled VOCs pattern could help early detection of chronic rejection allowing a prompt medical treatment.
- Being tested
- Breath analysis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Breath analysisOther
The breath of patients undergoing liver or kidney transplant will be sampled and volatile organic compounds will be identified
| Study group | Role | What they receive |
|---|---|---|
| Liver/kidney transplant | Experimental | The breath of patients undergoing liver or kidney transplant will be sampled and analysed Receives: Other: Breath analysis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Volatile organic compounds in end stage liver disease
to evaluate the pattern of volatile organic compounds in patients elegible for liver transplant
Measured: 30 days
Volatile organic compounds in end stage kidney disease
to evaluate the pattern of volatile organic compounds in patients elegible for kidney transplant
Measured: 30 days
Volatile organic compounds after liver transplant
to evaluate the pattern of volatile organic compounds able to identify the onset of chronic failure/rejection after liver transplants
Measured: 1 year
Volatile organic compounds after liver transplant
to evaluate the pattern of volatile organic compounds able to identify the onset of chronic failure/rejection after kidney transplants
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2020
- Study start2 Oct 2021 (estimated)
- Primary completion2 Oct 2022 (estimated)
- Study completion2 Mar 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver Transplant RejectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Societa Italiana di Chirurgia ColoRettale
- Sponsor type
- Research network
- Responsible party
- Sponsor
- Investigators
- Arcangelo Picciariello, MD, Principal investigator, Societa Italiana di Chirurgia ColoRettale
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04514666
- Sponsor's protocol ID
- 38/2020
- Status last verified
- Apr 2021
- First submitted
- 12 Aug 2020
- Last updated
- 20 Apr 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 20 Apr 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exhaled Volatile Organic Compounds as Potential Predictive Biomarkers of Chronic Kidney and Liver Rejection After Transplants
- ClinicalTrials.gov ID
- NCT04514666
- Acronym / sponsor ID
- 38/2020
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Societa Italiana di Chirurgia ColoRettaleResearch network
- Study start
- 2 Oct 2021 (estimated)
- Primary completion
- 2 Oct 2022 (estimated)
- Study completion
- 2 Mar 2023 (estimated)
- First posted
- 17 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Kidney and liver trasplants represent very challenging lifesaving and effective surgical procedures for patients with end-stage kidney and/or liver disease.
Chronic rejection may occur in 3 to 17% livers transplants and in 20 to 40% kidney transplants.
While acute rejection is clearly detected due to the clinical features and laboratory tools, the early identification of chronic rejection is still challenging since the clinical features are often silents and laboratory tests become suggestive when the damage due to the rejection is almost irreversible.
Considering the recent application of the breathomic to liver and kidney disease and the difficulty in the early detection of chronic rejection after liver and kidney transplants, the analysis of the exhaled VOCs pattern could help early detection of chronic rejection allowing a prompt medical treatment.
Detailed description
Kidney and liver trasplants represent very challenging lifesaving and effective surgical procedures for patients with end-stage kidney and/or liver disease.
Nowadays the short and long term success rate of kidney and liver trasplants is pretty hight. Nevertheless, transplant rejection remains one of the biggest limitations with a strong impact on patients survival.
Usually acute rejection occurs within 3 months after the transplant and is the most common cause of transplant failure and the most common indication for re-transplantation .
Chronic rejection may occur in 3 to 17% livers transplants and in 20 to 40% kidney transplants.
While acute rejection is clearly detected due to the clinical features and laboratory tools, the early identification of chronic rejection is still challenging since the clinical features are often silents and laboratory tests become suggestive when the damage due to the rejection is almost irreversible.
Chronic renal transplant rejection is the result of a gradual decrease in the kidney function that starts to become evident three months after surgery.
Kidney chronic rejection is, by definition, immune-mediated and generally divides into chronic active antibody-mediated rejection and chronic active T cell-mediated rejection.
Transplant vasculopathy is the single most important feature of chronic renal transplant rejection and it is the direct consequence of an immune reaction that activates a cytokines cascade with a tissue fibrosis and chronic rejection.
Hypertension and proteinuria are the most important features of declining renal function.
Laboratory tests such as serum creatinine and estimated glomerular filtration rate (eGFR)ccan help to early identify kidney allograft dysfunction. The eGFR is suggested to be a more accurate indicator and predictor of graft function and long term graft loss.
However, a biopsy is mandatory for diagnosing chronic renal transplant rejection. C4d complement fragment deposition in the peritubular capillaries represents the marker for antibody-mediated tissue injury.
Although the incidence of acute and chronic rejection has declined with improvement of immunosuppression regimens, chronic rejection may lead to re-transplant or death.
Chronic liver allograft rejection usually occurs more than 2 months after transplantation and most frequently develops after an unresolved or multiple episodes of acute rejection or indolently over a period of months to years, with few or no clinically apparent acute cellular rejection episodes.
Chronic rejection characterized primarily by fibrointimal hyperplasia of arteries, or obliterative arteriopathy, interstitial fibrosis and atrophy of parenchymal elements.
Often the only reliable early indicator of chronic rejection is persistent and preferential elevation of γ-glutamyl transpeptidase and alkaline phosphatase, which is related to bile duct damage. In most of cases the only clinical sign is jaundice and it appears when allograft dysfunction becomes. Biliary sludging or appearance of biliary strictures, hepatic infarcts, and finally loss of hepatic synthetic function, which can manifest as coagulopathy, malnutrition, and hepatosplenomegaly are late findings presaging allograft failure. Biopsy is mandatory to assess the liver damage.
Breath analysis (Breathomics) is applied widely nowadays in clinical setting in order to identify and evaluate exhaled molecular volatile compounds as expression of a metabolic derangement of the organism including chronic diseases and cancer disease.
A novel approach, a breath test based on the metabolomic evaluation of the volatile organic compounds (VOCs) in the exhaled breath, has recently been developed by our group to identify patients with Colorectal cancer, showing good reliability and compliance.
VOCs analysis has also been demonstrated to find an application in the diagnosis of chronic liver and kidney disease with high sensitivity and specificity.
Considering the recent application of the breathomic to liver and kidney disease and the difficulty in the early detection of chronic rejection after liver and kidney transplants, the analysis of the exhaled VOCs pattern could help early detection of chronic rejection allowing a prompt medical treatment.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Liver/kidney transplant | Experimental | Other: Breath analysisThe breath of patients undergoing liver or kidney transplant will be sampled and analysed |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Both sex
- Patients eligible for liver or kidney transplant
- Written informed consent
Key exclusion criteria (7 listed)
- Acute liver failure
- Acute liver and kidney rejection
- HCC
- Re-transplant
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Breath analysisThe breath of patients undergoing liver or kidney transplant will be sampled and volatile organic compounds will be identified | Other | Liver/kidney transplant |
Primary outcome
Volatile organic compounds in end stage liver disease
Time frame: 30 days
to evaluate the pattern of volatile organic compounds in patients elegible for liver transplant
Volatile organic compounds in end stage kidney disease
Time frame: 30 days
to evaluate the pattern of volatile organic compounds in patients elegible for kidney transplant
Volatile organic compounds after liver transplant
Time frame: 1 year
to evaluate the pattern of volatile organic compounds able to identify the onset of chronic failure/rejection after liver transplants
Volatile organic compounds after liver transplant
Time frame: 1 year
to evaluate the pattern of volatile organic compounds able to identify the onset of chronic failure/rejection after kidney transplants
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Apr 2021.
- Individual participant dataSharing planned: Undecided
Related trials for Liver Transplant Rejection
RecruitingObservational study
Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues
Heart Failure, Liver Fibrosis
RecruitingObservational study
Immune Biomarkers for Predicting Complications After Liver Transplantation
Liver Transplantation (LT), Immuno-suppression
RecruitingPhase 3
Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)
Liver Allograft, Liver Diseases
Enrolling by invitationObservational study
Global Utilization And Registry Database for Improved preservAtion of doNor Livers
Liver Diseases, Liver Dysfunction
Active, not recruitingPhase 1/2
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients
Rejection; Transplant, Liver, Liver Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Arcangelo Picciariello, MD principal investigator
Societa Italiana di Chirurgia ColoRettale
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Breath analysis in people with Liver Transplant Rejection and Kidney Transplant; Complications, run by Societa Italiana di Chirurgia ColoRettale at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Arcangelo Picciariello, MD (+393492185104, arcangelopicciariello@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Volatile organic compounds in end stage liver disease (time frame: 30 days). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2021.